Free Trial

Uncover Why This Pharma Stock Jumped 400% on Study Update

research scientist using micropipette filling test tubes

Key Points

  • Shares of Soligenix, a late-stage biopharmaceutical company, surged almost 400% today on breaking news.
  • The surge was triggered by an interim update on the promising results of the HyBryte™ treatment for early-stage cutaneous T-cell lymphoma.
  • Despite today's performance, the company faces challenges, with significant volatility and potential future capital needs.
  • 5 stocks we like better than Soligenix

Soligenix Today

Soligenix, Inc. stock logo
SNGXSNGX 90-day performance
-0.57 (-7.67%)
(As of 07/15/2024 ET)
52-Week Range

Soligenix Inc. NASDAQ: SNGX, a late-stage biopharmaceutical company, experienced an astonishing surge Tuesday. At the time of writing, the stock had soared nearly 400%. This dramatic increase, accompanied by a substantial rise in trading volume, warrants a closer look at the catalyst behind this movement and the company's fundamentals. 

This surge comes amidst increasing interest in small-cap stocks, which have seen a resurgence lately. Summer trading favors volatile market moves in low float names and has driven this resurgence.

Soligenix's Innovative Therapies

Soligenix focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte™), a novel photodynamic therapy, which has completed Phase III clinical trials for treating cutaneous T-cell lymphoma. Other pipeline products include SGX942 for treating inflammatory diseases, SGX302 for psoriasis, and SGX945 for aphthous ulcers in Behçet's Disease. These products represent potential breakthroughs in their respective fields, addressing areas of significant unmet medical need.

Catalyst for Soligenix's Stock Surge

The primary driver of the stock's surge is Soligenix's announcement of an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). Initial results are promising, with 75% of patients who completed at least 12 weeks of therapy achieving "Treatment Success," defined as a ≥50% improvement in their cumulative mCAILS score compared to baseline. Furthermore, HyBryte™ has been safe and well-tolerated, with no treatment-related adverse events reported. Dr. Ellen Kim, a leading figure in the CTCL treatment field, sponsored the trial, further adding credibility to the study's findings.

HyBryte™: Revolutionary Photodynamic Therapy

HyBryte™ (research name SGX301) is a novel, first-in-class photodynamic therapy that utilizes safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions and activated by visible light approximately 24 hours later. This treatment approach avoids the risk of secondary malignancies inherent with DNA-damaging drugs and other phototherapy reliant on ultraviolet exposure. In clinical studies, HyBryte™ has demonstrated significant anti-proliferative effects on malignant T-cells and has shown promise in treating both plaque and patch lesions of CTCL.

Soligenix's Stock Performance and Market Dynamics

Despite Tuesday's impressive performance, Soligenix has historically faced significant challenges. The stock remains negative year-to-date, even with the intraday gains, highlighting the volatility and speculative nature of the investment. The stock is highly susceptible to wild price movements, with a market capitalization of just $10 million and a free float of only 970,000 shares.

Tuesday's record volume of 120 million shares traded at the time of writing, compared to its average daily volume of just 150,000 shares, underscores this volatility. This volatility pattern is typical in small-cap stocks, which can experience dramatic price swings on the back of news and trading volume spikes.

Soligenix, Inc. (SNGX) Price Chart for Monday, July, 15, 2024

Soligenix last posted its quarterly earnings results on May 10, 2024. It reported ($2.88) earnings per share, beating analysts' estimates of ($3.20) by $0.32. The company earned $0.10 million during the quarter, compared to analyst estimates of $0.20 million.

As of March 31, the company had $7.1 million in cash and cash equivalents, providing it with sufficient runway based on its estimated cash burn of about $1.3 million per quarter. However, given that the company is pre-revenue when excluding grant funds, future capital raises through offerings are likely to fund its ongoing operations.

Important Considerations for Soligenix Investors

The stock's dramatic surge highlights the impact of positive clinical updates on small-cap biopharmaceutical stocks. While the initial results for HyBryte™ are promising, investors should be cautious due to the company's history of volatility and the potential need for future capital raises. The company's small market capitalization and limited float make it particularly susceptible to significant price fluctuations, posing risks for investors.

Should you invest $1,000 in Soligenix right now?

Before you consider Soligenix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soligenix wasn't on the list.

While Soligenix currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report
Ryan Hasson
About The Author

Ryan Hasson

Contributing Author

Technical Analysis, Momentum Trading, Risk Management

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Soligenix (SNGX)
0.7241 of 5 stars
0.72 / 5 stars
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

CPI News Breakdown: Key Market Moves to Follow

CPI News Breakdown: Key Market Moves to Follow

Join us as we break down the latest CPI news, its effect on your favorite stocks, and the broader market. We also discuss how these economic indicators might lead to a potential interest rate cut by t

Related Videos

Inside Pelosi’s Latest Stock Moves
4 Best Tech Stocks to Own in 2024
NVIDIA Tops Microsoft and Apple for Most Valuable Company

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines